Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervention, overall and stratified by race, and to evaluate the feasibility and acceptability of the PRISM intervention in the MBC population. Black women with MBC have shorter survival from the time of metastatic diagnosis to death, compared to White women with clinically similar disease, and may have more rapid declines in quality of life over time. Adverse social determinants of health may play a role in these outcome disparities, due to both social barriers in accessing care, and through direct stress-mediated biological effects on the host and tumor microenvironment. Interventions to reduce stress and optimize resilience during treatment of MBC may improve quality of life and even improve disease outcomes; however, feasibility of face-to-face intervention during intensive medical treatment is limited. Thus, this study aims to demonstrate the feasibility of a remotely delivered resilience intervention, PRISM, already proven effective in other cancer settings, for MBC patients, and to gather preliminary efficacy data for a future randomized trial.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wyrażona pisemna zgoda na udział w badaniu.
- •Uczestniczka musi być w stanie i chcieć brać udział w procedurach badawczych.
- •Wiek powyżej 18 lat.
- •Zdiagnozowany zaawansowany rak piersi (typ MBC) w ciągu ostatnich 6 miesięcy.
- •Umiejętność odpowiadania na pytania i uczestniczenia w sesjach wsparcia w języku angielskim.
- •Zamiar kontynuowania leczenia raka w ośrodku prowadzącym badanie.
✗ Disqualifies
- •Niechęć lub niemożność wypełniania ankiet (w formie papierowej lub elektronicznej).
- •Niechęć lub niemożność udzielenia zgody na udział (ustnej lub pisemnej).
- •Osoba nie potrafi czytać po angielsku.
- •Pacjentka, która zakończyła leczenie raka, nie zamierza go kontynuować, przebywa pod opieką hospicyjną, jest hospitalizowana lub przewiduje się, że umrze w ciągu 90 dni.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- May 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
The University of Alabama
Birmingham, United States
University of North Carolina
Chapel Hill, United States
Trial contact
Erin Laurie-Zehr
Kacee Little
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.